SEC Form 4 filed by CHIEF OPERATING OFFICER Soparkar Peter

6/20/25 4:29:48 PM ET

$ADVM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ADVM alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soparkar Peter

(Last)

(First)

(Middle)

C/O ADVERUM BIOTECHNOLOGIES, INC.

100 CARDINAL WAY

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Adverum Biotechnologies, Inc. [ ADVM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$68.8⁽¹⁾	06/17/2025		D⁽²⁾			40,000⁽¹⁾	⁽²⁾	10/29/2029	Common Stock	40,000⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽²⁾		40,000⁽¹⁾		⁽²⁾	10/29/2029	Common Stock	40,000⁽¹⁾	$0	40,000⁽¹⁾	D
Stock Option (Right to Buy)	$157.5⁽¹⁾	06/17/2025		D⁽³⁾			4,074⁽¹⁾	⁽³⁾	02/19/2030	Common Stock	4,074⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽³⁾		4,074⁽¹⁾		⁽³⁾	02/19/2030	Common Stock	4,074⁽¹⁾	$0	4,074⁽¹⁾	D
Stock Option (Right to Buy)	$134.4⁽¹⁾	06/17/2025		D⁽⁴⁾			13,999⁽¹⁾	⁽⁴⁾	02/15/2031	Common Stock	13,999⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽⁴⁾		13,999⁽¹⁾		⁽⁴⁾	02/15/2031	Common Stock	13,999⁽¹⁾	$0	13,999⁽¹⁾	D
Stock Option (Right to Buy)	$24.8⁽¹⁾	06/17/2025		D⁽⁵⁾			15,999⁽¹⁾	⁽⁵⁾	08/05/2031	Common Stock	15,999⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽⁵⁾		15,999⁽¹⁾		⁽⁵⁾	08/05/2031	Common Stock	15,999⁽¹⁾	$0	15,999⁽¹⁾	D
Stock Option (Right to Buy)	$12.9⁽¹⁾	06/17/2025		D⁽⁶⁾			25,500⁽¹⁾	⁽⁷⁾	03/07/2032	Common Stock	25,500⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽⁶⁾		25,500⁽¹⁾		⁽⁷⁾	03/07/2032	Common Stock	25,500⁽¹⁾	$0	25,500⁽¹⁾	D
Stock Option (Right to Buy)	$12.9⁽¹⁾	06/17/2025		D⁽⁶⁾			13,000⁽¹⁾	⁽⁸⁾	03/07/2032	Common Stock	13,000⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽⁶⁾		13,000⁽¹⁾		⁽⁸⁾	03/07/2032	Common Stock	13,000⁽¹⁾	$0	13,000⁽¹⁾	D
Stock Option (Right to Buy)	$10.9⁽¹⁾	06/17/2025		D⁽⁹⁾			23,092⁽¹⁾	⁽⁹⁾	09/13/2032	Common Stock	23,092⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽⁹⁾		23,092⁽¹⁾		⁽⁹⁾	09/13/2032	Common Stock	23,092⁽¹⁾	$0	23,092⁽¹⁾	D
Stock Option (Right to Buy)	$10.9⁽¹⁾	06/17/2025		D⁽¹⁰⁾			16,384⁽¹⁾	⁽¹¹⁾	09/13/2032	Common Stock	16,384⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽¹⁰⁾		16,384⁽¹⁾		⁽¹¹⁾	09/13/2032	Common Stock	16,384⁽¹⁾	$0	16,384⁽¹⁾	D
Stock Option (Right to Buy)	$19.9⁽¹⁾	06/17/2025		D⁽¹²⁾			45,000⁽¹⁾	⁽¹³⁾	02/11/2034	Common Stock	45,000⁽¹⁾	$0	0	D
Stock Option (Right to Buy)	$10.14	06/17/2025		A⁽¹²⁾		45,000⁽¹⁾		⁽¹³⁾	02/11/2034	Common Stock	45,000⁽¹⁾	$0	45,000⁽¹⁾	D

Explanation of Responses:

1. Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten.

2. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 30, 2019 and is fully vested.

3. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 20, 2020 and is fully vested.

4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 16, 2021 and is fully vested.

5. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on August 6, 2021 and is fully vested.

6. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 8, 2022.

7. Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 18, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 18, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.

8. The options vest in equal monthly installments over two years from August 16, 2023, such that all of the shares subject to the option shall become vested and exercisable as of August 16, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.

9. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 14, 2022 and is fully vested.

10. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 14, 2022.

11. The options vest in equal monthly installments over three years from September 14, 2022, such that all of the shares subject to the option shall become vested and exercisable as of September 14, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.

12. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 12, 2024.

13. Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.

	/s/ Aneta Fergson, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ADVM alert in real time by email

Recent Analyst Ratings for

$ADVM

Date	Price Target	Rating	Analyst
6/25/2024	$25.00	Outperform	Oppenheimer
4/30/2024	$30.00	Buy	H.C. Wainwright
7/7/2022	$4.00	Hold → Buy	Truist
7/23/2021		Hold → Neutral	Cantor Fitzgerald
7/23/2021	$23.00 → $3.00	Overweight → Neutral	Cantor Fitzgerald
7/23/2021	$5.00 → $2.00	Market Perform	SVB Leerink

More analyst ratings

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date (Month/Day/Year)

2A. Deemed Execution Date, if any (Month/Day/Year)

3. Transaction Code (Instr. 8)

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

Amount

(A) or (D)

Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to Buy)

$68.8⁽¹⁾

06/17/2025

D⁽²⁾

40,000⁽¹⁾

⁽²⁾

10/29/2029

Common Stock

40,000⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽²⁾

40,000⁽¹⁾

⁽²⁾

10/29/2029

Common Stock

40,000⁽¹⁾

Stock Option (Right to Buy)

$157.5⁽¹⁾

06/17/2025

D⁽³⁾

4,074⁽¹⁾

⁽³⁾

02/19/2030

Common Stock

4,074⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽³⁾

4,074⁽¹⁾

⁽³⁾

02/19/2030

Common Stock

4,074⁽¹⁾

Stock Option (Right to Buy)

$134.4⁽¹⁾

06/17/2025

D⁽⁴⁾

13,999⁽¹⁾

⁽⁴⁾

02/15/2031

Common Stock

13,999⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽⁴⁾

13,999⁽¹⁾

⁽⁴⁾

02/15/2031

Common Stock

13,999⁽¹⁾

Stock Option (Right to Buy)

$24.8⁽¹⁾

06/17/2025

D⁽⁵⁾

15,999⁽¹⁾

⁽⁵⁾

08/05/2031

Common Stock

15,999⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽⁵⁾

15,999⁽¹⁾

⁽⁵⁾

08/05/2031

Common Stock

15,999⁽¹⁾

Stock Option (Right to Buy)

$12.9⁽¹⁾

06/17/2025

D⁽⁶⁾

25,500⁽¹⁾

⁽⁷⁾

03/07/2032

Common Stock

25,500⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽⁶⁾

25,500⁽¹⁾

⁽⁷⁾

03/07/2032

Common Stock

25,500⁽¹⁾

Stock Option (Right to Buy)

$12.9⁽¹⁾

06/17/2025

D⁽⁶⁾

13,000⁽¹⁾

⁽⁸⁾

03/07/2032

Common Stock

13,000⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽⁶⁾

13,000⁽¹⁾

⁽⁸⁾

03/07/2032

Common Stock

13,000⁽¹⁾

Stock Option (Right to Buy)

$10.9⁽¹⁾

06/17/2025

D⁽⁹⁾

23,092⁽¹⁾

⁽⁹⁾

09/13/2032

Common Stock

23,092⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽⁹⁾

23,092⁽¹⁾

⁽⁹⁾

09/13/2032

Common Stock

23,092⁽¹⁾

Stock Option (Right to Buy)

$10.9⁽¹⁾

06/17/2025

D⁽¹⁰⁾

16,384⁽¹⁾

⁽¹¹⁾

09/13/2032

Common Stock

16,384⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽¹⁰⁾

16,384⁽¹⁾

⁽¹¹⁾

09/13/2032

Common Stock

16,384⁽¹⁾

Stock Option (Right to Buy)

$19.9⁽¹⁾

06/17/2025

D⁽¹²⁾

45,000⁽¹⁾

⁽¹³⁾

02/11/2034

Common Stock

45,000⁽¹⁾

Stock Option (Right to Buy)

$10.14

06/17/2025

A⁽¹²⁾

45,000⁽¹⁾

⁽¹³⁾

02/11/2034

Common Stock

45,000⁽¹⁾

Recent Analyst Ratings for

$ADVM

Date	Price Target	Rating	Analyst
6/25/2024	$25.00	Outperform	Oppenheimer
4/30/2024	$30.00	Buy	H.C. Wainwright
7/7/2022	$4.00	Hold → Buy	Truist
7/23/2021		Hold → Neutral	Cantor Fitzgerald
7/23/2021	$23.00 → $3.00	Overweight → Neutral	Cantor Fitzgerald
7/23/2021	$5.00 → $2.00	Market Perform	SVB Leerink

More analyst ratings

SEC Form 4 filed by CHIEF OPERATING OFFICER Soparkar Peter

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $ADVM

SEC Form 4 filed by CHIEF OPERATING OFFICER Soparkar Peter

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $ADVM

$ADVM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

$ADVM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Adverum Biotech with a new price target

H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

Adverum Biotech upgraded by Truist with a new price target

$ADVM SEC Filings

SEC Form S-8 filed by Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form DEFA14A filed by Adverum Biotechnologies Inc.

$ADVM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by CHIEF OPERATING OFFICER Soparkar Peter

SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh

SEC Form 4 filed by CHIEF FINANCIAL OFFICER Rubinstein Linda M

$ADVM Press Releases

Fastest customizable press release news feed in the world

Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream

Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$ADVM Financials

Live finance-specific insights

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

$ADVM Leadership Updates

Live Leadership Updates

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

$ADVM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

Recent Analyst Ratings for
$ADVM

Recent Analyst Ratings for
$ADVM

$ADVM
Insider Purchases

$ADVM
Analyst Ratings

$ADVM
SEC Filings

$ADVM
Insider Trading

$ADVM
Press Releases

$ADVM
Financials

$ADVM
Leadership Updates

$ADVM
Large Ownership Changes